CEBPB and Hepatic fibrosis: In agreement with the results observed after CCl4 treatment in mice expressing the C/EBPβ-Ala217 transgene, treatment with the RSK-inhibitory peptide of C/EBPβ+/+ mice with severe liver fibrosis induced by CCl4, while continuing to receive CCl4, reduced the following: i) expression of liver fibrogenic indicators such as collagen α 1 type 1 mRNA (P<0.05), α-SMA mRNA (activated HSC) (P<0.05), and TGF-β mRNA (fibrogenic cytokine) (P<0.01) (Figure 2A, B, and C); and ii) recruitment of CD-68+ inflammatory cells to the liver (Figure 3A).